close

Fenwick Represents Agilent Technologies in $80 Million Investment in Lasergen

Fenwick & West represented Agilent Technologies Inc., a global leader in life sciences, diagnostics and applied chemical markets, in its $80 million investment in Lasergen, a privately held emerging biotechnology company with innovative next-generation sequencing technology. With the investment, Agilent will acquire a 48-percent ownership stake in Lasergen and will join the board.

The two companies will collaborate on building a next-generation sequencing solutions workflow for clinical applications, based on Lasergen's Lightning Terminators(tm) sequencing chemistry. More information about Agilent’s $80 million investment in Lasergen can be obtained from the company press release.

The Fenwick transaction team was led by corporate attorneys Michael Brown, Andrew Luh, Vishal Dave, ​and Maureen Montgomery; technology transactions attorney Jake Handy; and employee benefits attorney Liz Gartland.​​